Ignite Creation Date:
2025-12-25 @ 3:45 AM
Ignite Modification Date:
2026-01-29 @ 2:32 AM
Study NCT ID:
NCT01326702
Status:
COMPLETED
Last Update Posted:
2019-12-16
First Post:
2011-03-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
Sponsor:
National Cancer Institute (NCI)
Organization:
Organization Data
Organization:
Class:
NIH
Study ID:
NCI-2011-02583
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
NIH
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None